Appointments

Prior to his role at Oxford Biomedica, Dr Mathias worked as CEO of Rentschler Biopharma SE from 2016. In 2019, Dr Mathias was awarded the title of ‘EY Enterpreneur of the Year’ in Germany. Before working at Rentschler, he was CEO of immuno-oncology company, Medigene AG, where his work focused on developing T cell-based cancer treatments.

In March 2023, Dr Roch Doliveux will step down as Interim CEO, at which point Dr Mathias will take his role, while Dr Doliveux will take the role of non-executive chair.

Dr Roch Doliveux commented on the appointment, stating: “Frank is an outstanding patient-centric leader with impressive experience from a top-end CDMO as well as from innovative biopharma companies. He has a strong track record of delivering growth and driving performance and innovation, which are core strengths required to implement our strategy of becoming an innovative global viral vector leader.”

Dr Frank Mathias added: “Oxford Biomedica is a world-leader in the innovative development and manufacture of viral vectors for life-saving cell and gene therapies, demonstrated by the ever-expanding customer base of now more than 20 programmes across all vector types.”